ForeseeHome
Helping doctors diagnose wet AMD earlier for better outcomes
Device · HybridCompany source
Company profile
About Notal Vision Inc
Notal Vision is a pioneering digital health company that extends eye disease management from the clinic to the home, addressing unmet diagnostic needs in ophthalmology through precision medicine. The company has developed a proven approach combining home-based, patient-operated diagnostics with artificial intelligence-enabled data analysis to advance eye care outcomes. Their flagship product, ForeseeHome, helps doctors diagnose wet AMD earlier, validated through the AREDS2 HOME Study involving 1,520 patients that demonstrated significant vision benefits. The company also offers SCANLY Home OCT, which provides actionable insights between office visits for wet AMD care. Notal Vision operates a comprehensive Monitoring Center, a Medicare-recognized Independent Diagnostic Testing Facility (IDTF) directed by practicing ophthalmologists and supported by certified ophthalmic professionals. This center serves as the epicenter for patient and physician engagement, providing 24/7 connectivity, real-time automated analysis of patient testing data, and comprehensive support services. Founded in Tel Aviv and now headquartered in Manassas, Virginia, Notal Vision combines innovative Israeli R&D with veteran industry leadership. The company's approach enables treatment decisions based on each patient's disease activity rather than pre-scheduled clinic appointments, bringing precision medicine to eye care through novel diagnostic data and AI-driven analysis.
Company description Notal Vision Inc official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Notal Vision Inc?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Age-related Macular Degeneration (AMD)
- Dry AMD
- Retinal diseases
- Wet AMD
Who it serves
- AMD patients
- Eye care practices
- Ophthalmologists
- Retina specialists
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
FDA de novo marketing authorization for SCANLY Home OCT breakthrough designation device (2024), AI-powered daily home OCT analysis capabilities (2025)
Partnerships
Recorded partners
- US National Eye Institute (AREDS2 HOME Study collaboration)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Notal Vision Monitoring Center
Remote patient monitoring services connecting patients and physicians 24/7
Service · Cloud SaaSCompany source
SCANLY Home OCT
Advancing wet AMD care through actionable insights between office visits
Device · HybridCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Longitudinal Validation of the Artificial Intelligence Algorithm in Home OCT for Age-Related Macular Degeneration-Report 3.Ophthalmology science · Feb 1, 2026
Home Monitoring for the Management of Age-Related Macular Degeneration: A Review of the Development and Implementation of Digital Health Solutions over a 25-Year Scientific Journey.Medicina (Kaunas, Lithuania) · Dec 11, 2025
Pivotal Trial Validating Usability and Visualization Performance of Home OCT in Neovascular Age-Related Macular Degeneration: Report 1.Ophthalmology science · Jan 1, 2025
Pivotal Trial Toward Effectiveness of Self-administered OCT in Neovascular Age-related Macular Degeneration. Report 2-Artificial Intelligence Analytics.Ophthalmology science · Jan 1, 2025
Evaluation of a Self-Imaging SD-OCT System for Remote Monitoring of Patients with Neovascular Age Related Macular Degeneration.Klinische Monatsblatter fur Augenheilkunde · Dec 1, 2020
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Notal Vision Home Optical Coherence Tomography (OCT) SystemDEN230043 · De Novo · May 15, 2024
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Earlier wet AMD diagnosis
ForeseeHome enables earlier detection of progression from dry to wet AMD
34% of eyes retain driving vision at wet AMD diagnosis
Baseline comparison showing need for earlier detection
Better vision outcomes
AREDS2 HOME Study demonstrated significant vision benefits with home monitoring
AREDS2 HOME Study (National Eye Institute)
Large randomized clinical trial evaluating ForeseeHome for early detection of wet AMD progression in dry AMD patients
1,520 dry AMD patients monitored; demonstrated highly significant vision benefits upon progression to wet AMD
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Kester Nahen
Chief Executive Officer
Gidi Benyamini
Chief Scientific Officer
Ofer Aizikovich
Vice President, Engineering & Manufacturing
Barbara Benedict
Vice President, Strategy & Operations
Nishant Mohan
Vice President of Product
David Rachutin
Vice President, Cloud Software Development & IT Systems
George E Sanborn
Medical Director
Jennifer Jacobs
Medical Director
06 · Company updates
Updates from Notal Vision Inc
Recent articles published on Notal Vision Inc's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.